The Pharma Data

FEBRUARY 24, 2022

Their findings are published online in Nature Cell Biology. “We are amazed by the efficiency of small-molecule PROTAC in simultaneously targeting EZH2 and cMyc in cancer cells.” MS177 targets both EZH2 and cMyc and thus inhibit cancer growth.

Small Molecule 52

Small Molecule Cell Biology Research Drug Development 52

Alta Sciences

JANUARY 31, 2025

As experts in early-phase drug development , from discovery through Phase II clinical research , we at Altasciences can share with STC members our accumulated knowledge and experience, and provide mentorship for future toxicologists. Their passion and curiosity to expand the boundaries of toxicology research illuminated the room.

Cell Biology 52

Cell Biology Pharmaceutical Companies Clinical Research Government 52

NIH Director's Blog: Drug Discovery

APRIL 11, 2017

Before testing their peptides in animal models, they’ll continue to tinker with them in search of a version effective in disabling iPGM that might also make its way into cells more easily. Drug development is a notoriously long and arduous process, which too often ends in disappointment. Nat Commun. 2017 Apr 3;8:14932.

Small Molecule 52

Small Molecule Science Drug Development Disease 52

Elrig

APRIL 29, 2024

Driven by an interest in drug discovery Millie joined AstraZeneca after completion of her PhD at the end of 2020. As an early career professional (ECP) herself, Millie is currently a member of ELRIG’s ECP workgroup, and is excited to co-chair her first webinar.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

NIH Director's Blog: Drug Development

SEPTEMBER 20, 2018

But after a few seconds, our eyes are able to adjust and see in the near-dark, thanks to a protein called rhodopsin found at the surface of certain specialized cells in the retina, the thin, vision-initiating tissue that lines the back of the eye.

Laboratories 52

Laboratories Research Drugs Regulations 52

DrugBank

JUNE 27, 2023

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.

Disease 87

Disease Treatment Drugs Clinical Trials 87

New Drug Approvals

JANUARY 9, 2024

As such, it has been proposed that inhibiting CDK7 would provide a potent means of inhibiting cell cycle progression, which may be especially relevant given that there is compelling evidence from gene knockout studies in mice for lack of an absolute requirement for CDK2, CDK4 and CDK6 for the cell cycle at least in most cell types (M alumbres et al.,

Production 62

Production DNA RNA Regulations 62

Codon

APRIL 9, 2024

Department of Defense administered mefloquine, the synthetic drug developed at Walter Reed in the U.S., only issued “the strongest ‘black box’ warning” against the drug in 2013. have been poured into replicating work already done” by Chinese scientists decades ago. Nobody had an answer.

Drugs 137

Drugs Science Research Doctors 137

Drug Target Review

JANUARY 16, 2025

She has a PhD in Microbiology and Cell Biology from the University of Illinois, followed by work in biochemistry as a post-doctoral fellow at UCSF. About the authors Ann E Cleves Ann is VP of Application Science for Optibrium s BioPharmics Division, which focuses on 3D computational modelling for molecular design.

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52

Broad Institute

NOVEMBER 21, 2024

Bernstein is also chair of the Department of Cancer Biology at Dana-Farber Cancer Institute, a professor in cell biology and pathology at Harvard Medical School, and holds the Richard and Nancy Lubin Family Chair. Inevitable progression Gliomas arise from glial cells, which protect and support a healthy nervous system.

Research 124

Research Medical Schools DNA Hospitals 124

Drug Target Review

APRIL 1, 2025

Founded in 2021, SynaptixBio is working to develop therapies for TUBB4A leukodystrophies – a group of rare and severe neurological disorders. Co-founder and CEO Dr Dan Williams brings over 20 years of experience in biochemistry and drug development, with a strong background in research and clinical trials.

Disease 52

Disease Therapies Clinical Trials Cell Biology 52

SugarCone Biotech

MAY 28, 2019

Learnings regarding immune geography and cell:cell contact are increasingly important as we consider how best to advance cell therapies for diverse hematologic malignancies and solid tumors ( www.aletabio.com ). This was an interesting finding and one that I think remains under-appreciated by the immuno-oncology drug development field.

Immune Response 52

Immune Response Therapies Engineering Drug Development 52